We are committed to advancing the treatment of eye conditions such as keratoconus and corneal ectasia following refractive surgery, through the continued innovation of our corneal cross-linking technology and pharmaceuticals. We develop products that are not only state-of-the-art but uphold the highest levels of quality and safety. Source
No articles found.
Champions Oncology, Inc. is engaged in the development of advanced technology solu...
Champions Oncology, Inc. is engaged in the deve...
We are a late-stage biopharmaceutical company dedicated to bringing transformative...
We are a late-stage biopharmaceutical company d...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
Founded in 1998, GW is a biopharmaceutical company focused on discovering, develop...
Founded in 1998, GW is a biopharmaceutical comp...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonan...
IRADIMED CORPORATION is a leader in the develop...
Join the National Investor Network and get the latest information with your interests in mind.